Cisplatin
- Generic Name
- Cisplatin
- Brand Names
- Platinol
- Drug Type
- Small Molecule
- Chemical Formula
- Cl2H6N2Pt
- CAS Number
- 15663-27-1
- Unique Ingredient Identifier
- Q20Q21Q62J
- Background
Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.
- Indication
For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.
- Associated Conditions
- Advanced Ovarian Cancer, Ovarian Cancer Metastatic, Advanced Bladder cancer, Advanced Testicular cancer, Metastatic Testicular cancer
- Associated Therapies
- -
Cadonilimab in the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2023-06-12
- Last Posted Date
- 2023-06-12
- Lead Sponsor
- Guangxi Medical University
- Target Recruit Count
- 20
- Registration Number
- NCT05898256
Effect of Sodium Thiosulfate on Nephrotoxicity of Cisplatin Intraperitoneal Heat-perfusion Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2023-05-26
- Last Posted Date
- 2023-05-26
- Target Recruit Count
- 110
- Registration Number
- NCT05877911
A Phase III Study of SKB264 for EGFR Mutant NSCLC Patients
- Conditions
- Interventions
- First Posted Date
- 2023-05-23
- Last Posted Date
- 2023-08-08
- Target Recruit Count
- 356
- Registration Number
- NCT05870319
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Neoadjuvant Treatment of Tislelizumab Combined Chemotherapy for Locally Advanced Oral Squamous Cell Carcinoma ：A Single-arm, Prospective, Phase II Trial
- Conditions
- Interventions
- First Posted Date
- 2023-05-17
- Last Posted Date
- 2023-07-17
- Lead Sponsor
- Weijia Fang, MD
- Target Recruit Count
- 30
- Registration Number
- NCT05862168
- Locations
- 🇨🇳
First affiliated hospital, School of Medicine, Zhejiang University, Hangzhou, China
Postoperative Hypofractionated Radiation in Cervical and Endometrial Tumours: Phase II Study
- Conditions
- Interventions
- First Posted Date
- 2023-05-12
- Last Posted Date
- 2023-11-22
- Lead Sponsor
- Tata Memorial Centre
- Target Recruit Count
- 90
- Registration Number
- NCT05857631
- Locations
- 🇮🇳
Advanced Centre for Treatment Research and Education in Cancer (ACTREC), Navi Mumbai, Maharahstra, India
🇮🇳Tata Memorial Hospital, Mumbai, Maharashtra, India
Gemcitabine and Camrelizumab Plus Apatinib Versus Cisplatin in First-line Treatment of RM-NPC
- Conditions
- Interventions
- First Posted Date
- 2023-05-11
- Last Posted Date
- 2023-05-11
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 244
- Registration Number
- NCT05854849
- Locations
- 🇨🇳
Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Interval Cytoreductive Surgery With or Without HIPEC for Ovarian Cancer (KOV-HIPEC-04)
- First Posted Date
- 2023-04-25
- Last Posted Date
- 2023-06-01
- Lead Sponsor
- National Cancer Center, Korea
- Target Recruit Count
- 520
- Registration Number
- NCT05827523
- Locations
- 🇰🇷
National Cancer Center, Goyang, Gyeonggi, Korea, Republic of
Envafolimab Combined With Abraxane and Cisplatinas as Neoadjuvant Treatment for Resectable Esophageal Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-04-25
- Last Posted Date
- 2023-04-25
- Lead Sponsor
- Fujian Medical University Union Hospital
- Target Recruit Count
- 33
- Registration Number
- NCT05828381
Valproic Acid/Simvastatin Plus Gemcitabine/Nab-paclitaxel Based Regimens in Untreated Metastatic Pancreatic Adenocarcinoma Patients
- Conditions
- Interventions
- First Posted Date
- 2023-04-20
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- National Cancer Institute, Naples
- Target Recruit Count
- 240
- Registration Number
- NCT05821556
- Locations
- 🇮🇹
Università vita e Salute, IRCCS San Raffaele, Milano, Italy
🇮🇹Istituto Nazionale Tumori di Napoli - IRCCS - Fondazione G. Pascale, Napoli, Italy
🇮🇹University of Verona Hospital Trust, Verona, Italy
Immunotherapy Plus Chemotherapy vs. Chemoradiotherapy for Thoracic Squamous Esophageal Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2023-04-20
- Last Posted Date
- 2023-04-20
- Lead Sponsor
- Fujian Medical University Union Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT05821452
- Locations
- 🇨🇳
Fujian Medical University Union Hospital, Fuzhou, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.